23rd Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease
4 – 6 March 2026 | Kraków, Poland

Abstract Title List 2026

Selected for Oral Abstract Presentation | *Selected for Mini Oral Presentation* | *Selected for Poster Stage Presentation*
** Shared 1st Authorship*

A | Clinical Science – Epidemiology incl. Registries

A01 **Arab, A. et al.** Clinicopathological characteristics and outcomes of patients with neuroendocrine neoplasms: A single-center retrospective study

A02 **Baldini, L. et al.** Gastrointestinal neuroendocrine tumors in early onset patient: A retrospective study in an ENETS Center of Excellence

A03 **Belabdi, D. et al.** Frequency of carcinoid heart disease in a cohort of patients with neuroendocrine neoplasms: A retrospective analysis

A04 **Belabdi, D. et al.** Real-world data of digestive NENs management in our context: Are we good with what we have?

A05 **Bogaards, M. et al.** Adherence to the Mediterranean diet and risk of neuroendocrine tumor development

A06 **Brach, L. et al.** Choroidal metastases from neuroendocrine tumors: What oncologists should know

A07 **Chen, L. et al.** Management of neuroendocrine neoplasms: Are we making progresses?

A08 **Chen, J. et al.** Mapping patient experiences: Addressing gaps in care for people in China living with neuroendocrine tumours

A09 **Cheng, D. et al.** Clinical outcomes of resected pulmonary NETs at an Australian tertiary referral centre

A10 **Cheng, D. et al.** Clinical utility of molecularly profiling in gastroenteropancreatic neuroendocrine tumours from a retrospective multi-centre cohort study in the United Kingdom

A11 **Cheng, D. et al.** Real-world clinical outcomes of patients with metastatic pulmonary NETs at a single tertiary center

A12 **Choi, S. et al.** De-novo versus transformed prostate neuroendocrine carcinoma: A population-based study of 1,326 patients

A13 **Clift, A. et al.** Evolution of management and outcomes for neuroendocrine liver metastases over three decades: An international, multi-centre cohort study

A14 **Corrêa Figueira, C. et al.** Adrenal tumors: Navigating the neuroendocrine divide – Single-center 13-year experience in pheocromocytoma and adrenal adenoma

A15 **Cruz-Diaz, W. et al.** Epidemiologic trends and survival outcomes of gastroenteropancreatic neuroendocrine tumors in Peru: A 15-year retrospective cohort from a national referral center

A16 **Dai, S. et al.** Clinicopathological features and survival outcomes of small gastroenteropancreatic neuroendocrine tumors: A multi-site comparative study based on SEER database

A17 **Dasari, A. et al.** Grade distribution across primary sites in neuroendocrine neoplasms: A population-based SEER analysis

A18 **Di Nola, M. et al.** Metastases in sporadic neuroendocrine neoplasms: Experience from a tertiary care center

A19 **Diamantopoulos, L. et al.** Development and validation of a novel prognostic model for overall survival in patients with cervical neuroendocrine carcinoma

A20 **Garcia Ramos, A. et al.** Characterization of patients diagnosed with well and poorly differentiated neuroendocrine neoplasms in a tertiary institution in Cali, Colombia (2010–2023)

A21 **Ghandilyan, E. et al.** Diagnostic pathways in neuroendocrine neoplasms: A retrospective study of patient journeys from first symptoms to diagnosis

A22 **González Clavijo, A. et al.** Multi-center study in Colombia on the characterization of patients diagnosed with parathyroid carcinoma

A23 **González Devia, D. et al.** Cardiovascular risk in acromegaly

A24 **Kobawaka Gamage, K. et al.** Prescription of hormone replacement therapy in women with neuroendocrine tumours: Patterns and predictors from a UK Centre of Excellence

A25 **Kolodziej, M. et al.** The Polish RLT Registry: A comprehensive real-world portrait of NET patients undergoing [177Lu]Lu-DOTA-TATE therapy

A26 **Konyakhina, A. et al.** Paraganglioma registry analysis at the A. S. Loginov Moscow Clinical Scientific Center

A27 **Konyakhina, A. et al.** Pulmonary neuroendocrine tumors across disease stages: Management patterns and outcomes in the A. S. Loginov MCSC registry (2015–2025)

A28 **Krug, S. et al.** A cancer registry analysis of neuroendocrine neoplasms in Germany

A29 **Lickova, K. et al.** Carcinoid syndrome frequency in cases from Czech NEN registry

A30 **Martinez-Badal, S. et al.** How to advance toward a combined analysis of clinical trials in neuroendocrine tumors? Harmonization and standardization of 10 GETNE studies as a preliminary step for AI-based analysis

A31 **Matthaiou, C. et al.** Epidemiology, diagnostic, and therapeutic patterns of neuroendocrine tumors in Cyprus: Real-world data from a multi-center registry

A32 **Mortagy, M. et al.** Demographic and clinical characteristics of patients undergoing surgery for pancreatic neuroendocrine tumours (PanNET): A retrospective population-based analysis of 11,934 patients comparing England and the USA

A33 **Mortagy, M. et al.** Novel machine learning survival models for prediction and risk stratification of 8,435 pancreatic neuroendocrine tumour patients

A34 **Nordstrand, M. et al.** Incidence and distribution of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN): A 20-year population-based study from south-west Norway (2003-2022)

A35 **Peixoto, S. et al.** Neuroendocrine tumors: Clinical profile and outcomes in a single-center tertiary oncology cohort

A36 **Rosero, D. et al.** Neuroendocrine neoplasms in young adults: Clinicopathologic profile and survival – Outcomes from the R-GETNE registry

A37 **Rossi, R. et al.** Neuroendocrine tumors in patients with inflammatory bowel disease: A true association or just a coincidence?

A38 **Salimgereeva, D. et al.** PanNET registry: Disease staging, treatment pathways, and survival outcomes

A39 **Schulz, L. et al.** Outcome of multimodal treatment options in patients with gastroenteropancreatic neuroendocrine tumors: A real-world data analysis from the Medical Center Freiburg, Germany

A40 **Shekhda, K. et al.** Pancreatic neuroendocrine tumours in patients with tuberous sclerosis complex: A multi-centre retrospective study

A41 **Shekhda, K. et al.** Referral pathway to an ENETS Centre of Excellence for optimal management of paediatric neuroendocrine tumour patients

A42 **Shekhda, K. et al.** The clinico-pathological spectrum and outcomes of somatostatinoma: A case series and experience from an ENETS Centre of Excellence

A43 **Spyroglou, A. et al.** Von-Hippel Lindau syndrome and chronic autoimmune gastritis – Just a coincidence?

A44 **Trama, A. et al.** Towards improved neuroendocrine neoplasms registration – The experience of the AIRTum Itanet collaboration

A45 **Zoboli, F. et al.** Clinicopathological characteristics and survival determinants of duodenal and ampullary neuroendocrine tumors: A population-based retrospective analysis from the SEER database

B | Clinical Science – Clinical Pathology

B01 **Benevento, E. et al.** Proton pump inhibitors and tumor grade in gastric neuroendocrine tumors: Are we fueling the fire?

B02 **Chhajlani, S. et al.** PRRT-associated NET to NEC dedifferentiation

B03 **Gao, C. et al.** Significant intra-pancreatic fat deposition as an independent prognostic factor in high-grade pancreatic neuroendocrine neoplasms

B04 **Halperin, R. et al.** The GAPP aggressivity score correlates with total somatic non-missense

mutation burden in pheochromocytoma

B05 **Hekman, I. et al.** From eyeballing to deep learning: Comparing manual and automated methods to assess the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)

B06 **Jiayu, L. et al.** Clinicopathologic characteristics of neuroendocrine neoplasms diagnosed at a single tertiary center: A five-year retrospective analysis (2020–2025)

B07 **Khalifa, S. et al.** The value of double reading in the diagnosis of neuroendocrine tumors: Experience of the pathology and cytology department at EHU Oran regarding a series of 211 cases

B08 **Konyakhina, A. et al.** Gastric mucosa histopathology in gastric neuroendocrine neoplasia type 1: OLGA protocol findings

B09 **Liu, Z. et al.** Clinicopathological characteristics and prognosis of pheochromocytomas and paragangliomas (PPGLs) in 235 patients

B10 **Lopes, M. et al.** Obstructive biliary tract disease is associated with impaired survival in neuroendocrine tumor patients

B11 **Mortagy, M. et al.** Not all liver metastases are equal in gastroenteropancreatic neuroendocrine tumours: A population-based study of survival in 47,489 patients

B12 **Peregorodiev, I. et al.** Immunohistochemical analysis of Rb and p53 status in gastric NENs

B13 **Qiongyan, Z. et al.** Genetic profile of 25 paired pancreatic neuroendocrine tumors with liver metastases

B14 **Sabella, G. et al.** Clinicopathological features and prognostic factors in gastric neuroendocrine neoplasms: A single-center retrospective analysis of 81 cases

B15 **Sheikh-Ahmad, M. et al.** Immunohistochemical expression of somatostatin receptors 2 and 5 and dopamine D2 receptor in neuroendocrine tumors: Associations with grade and proliferation

B16 **Tasouli, E. et al.** The use of cold somatostatin analogue therapy in metastatic phaeochromocytomas and paragangliomas: A single-centre retrospective analysis

B17 **Tihy, M. et al.** Clinical impact of variability in digital Ki-67 assessment: Platform differences threaten accuracy in high-grade digestive neuroendocrine neoplasms

B18 **Tsoli, M. et al.** Grade 2 gastric neuroendocrine neoplasms type 1: Do they behave similarly to grade 1 tumours?

B19 **Wang, R. et al.** TROP2 in digestive NENs: Expression, prognostic significance, and association with YAP1

B20 **Wu, B. et al.** MAGE-A4 expression and its clinicopathological correlations in neuroendocrine carcinoma

B21 **Xu, L. et al.** Therapeutic target expression of CLDN18.2, DLL3, B7-H3and TROP2 in extrapulmonary neuroendocrine carcinoma: An immunohistochemical analysis

B22 **Yin, L. et al.** Molecular features of gastroenteropancreatic high-grade neuroendocrine

neoplasm

B23 **Zahoor, D. et al.** Clinicopathological spectrum of gastroenteropancreatic neuroendocrine neoplasms: A retrospective study at a tertiary care hospital in Karachi, Pakistan

B24 **Zhou, Y. et al.** Clinicopathological and molecular characteristics of neuroendocrine neoplasms of the extrahepatic biliary system and gallbladder

C | Clinical Science – Clinical Biomarkers

C01 **Ahsan, M. et al.** Profiling plasma cfDNA in germline and sporadic NENs using shallow whole genome sequencing

C02 **Amin, T. et al.** High fibrinogen and CRP predict poor survival after surgery for pancreatic neuroendocrine tumors

C03 **Anton-Pascual, B. et al.** Spatial immune landscape identifies microenvironmental predictors of immunotherapy efficacy in grade 3 digestive neuroendocrine neoplasms

C04 **Apostolidis, L. et al.** Clinical relevance of comprehensive genomic and transcriptomic profiling in advanced epithelial neuroendocrine neoplasms: Results from the MASTER precision oncology program

C05 **Bivolarski, I. et al.** Timing of somatostatin analogue administration and symptom control in neuroendocrine tumors: A real-world analysis integrating clinical and chronobiological parameters

C06 **Boehm, E. et al.** Diagnostic and therapeutic impact of genomic testing in 2650 neuroendocrine neoplasms from the AACR GENIE Database and a real-world ENETS Centre of Excellence cohort

C07 **Corrêa Figueira, C. et al.** Clinicopathological and prognostic factors of non-pancreatic gastrointestinal NEN – Single-center 11-year retrospective review

C08 **Cristiana, M. et al.** Clinical and molecular characterization of adolescents and young adults with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN): The YOUNGSTER study

C09 **Duan, X. et al.** Whole-exome sequencing reveals distinct genomic landscapes and prognostic biomarkers in primary unknown hepatic neuroendocrine neoplasms

C10 **Feng, M. et al.** Visualized clinical-radiomics model based on non-contrast computed tomography for predicting efficacy of surufatinib in hepatic metastases of neuroendocrine neoplasms

C11 **Fernández, D. et al.** Initial external validation of the TB-NET Score evaluating tumor burden (TB) in well-differentiated (wd) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

C12 **Gao, C. et al.** Prognostic value of the preoperative monocyte/high-density lipoprotein cholesterol ratio in non-functional pancreatic neuroendocrine tumors

C13 **Gervaso, L. et al.** Claudin 18.2 assessment in high-grade neuroendocrine neoplasms: The

ClaudiNET study

C14 **Grewal, U. et al.** Molecular and immune landscape of early-onset versus average-onset well-differentiated enteropancreatic neuroendocrine tumors

C15 **Hao, Y. et al.** Single-cell RNA-seq dissection of the heterogeneous immune landscape across molecular subtypes in pancreatic neuroendocrine tumors

C16 **Jiang, Q. et al.** Tertiary lymphoid structures predict favorable prognosis in pancreatic neuroendocrine tumors with liver metastasis: A comprehensive analysis from clinicopathology to the tumor microenvironment

C17 **Komarnicki, P. et al.** What can we learn from blood morphology? Case-control study of systemic inflammatory and hematological indices in pancreatic and small intestinal NETs

C18 **Lau, T. et al.** Effect of telotristat ethyl on circulating extracellular matrix biomarkers of fibrogenesis: Implications for carcinoid heart disease and mesenteric fibrosis

C19 **Leunissen, D. et al.** Loss of ATRX and DAXX expression is infrequent and not associated with prognosis in pulmonary carcinoids

C20 **Mancini, C. et al.** Mutational profiling of circulating tumor DNA in GEP-NETs: Results from a WES analysis for the definition of prognostic biomarkers and therapeutic targets

C21 **Nisman*, B. et al.** ProGRP as a biomarker in lung carcinoids associated with DIPNECH

C22 **Opalinska, M. et al.** Evaluation of novel serum biomarkers for detection and monitoring of neuroendocrine tumors

C23 **Paravani, P. et al.** Predictive model of postoperative recurrence in pulmonary NETs

C24 **Perrier, M. et al.** Defining Ki-67 threshold for metastatic low and high-G2 pancreatic NETs: A French national NET database analysis

C25 **Riechelmann, R. et al.** Clinical outcomes of patients with treatment-induced hypermutated pancreatic neuroendocrine tumors (PanNET) not treated with immune checkpoint inhibitors

C26 **Rosiek, V. et al.** Diagnostic and predicting value of serum CA19-9, CEA and chromogranin A in patients with pancreatic neuroendocrine neoplasm

C27 **Rosiek, V. et al.** Serum leptin as a metabolic biomarker in lung neuroendocrine neoplasms

C28 **Ruikang, D. et al.** AGR2 complements ATRX/DAXX to improve PFS risk stratification in NF-PanNETs

C29 **Skalniak, A. et al.** Gut microbiome dysbiosis and cognitive dysfunction in carcinoid syndrome: Comparative analysis of neuroendocrine neoplasm patients

C30 **van der Slik, E. et al.** Serum proteomic profiling for mesenteric fibrosis in SI-NETs: An exploratory biomarker study

C31 **van Weert, T. et al.** OTP, CD44, Ki-67 immunohistochemistry to predict prognosis in preoperative lung neuroendocrine tumor biopsy specimens

C32 **Wojcik-Giertuga, M. et al.** Assessment of the selected coagulation parameters in risk

prediction of the venous thromboembolic events in neuroendocrine tumours

C33 **Xu, J. et al.** Clinical characteristics and survival outcomes of extrapulmonary neuroendocrine carcinomas: A retrospective study

C34 **You, T. et al.** NETest can predict disease progression in neuroendocrine tumors

D | Clinical Science – Imaging & Nuclear Medicine: Diagnosis and Therapeutic

D01 **Acuña Hernandez, M. et al.** Cost-utility of therapy with 177Lu-DOTAPEPTIDE: Systematic review of the literature

D02 **Akram, F. et al.** Pulmonary neuroendocrine tumour artificial intelligence-assisted prediction of postoperative recurrence from tumour biopsy specimens

D03 **Baudoux, N. et al.** Real-world clinical outcomes of peptide receptor radionucleotide therapy in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors

D04 **Bogner, B. et al.** Deep learning–based whole-body composition analysis from routine staging CT predicts survival in patients with neuroendocrine tumors beyond established risk factors

D05 **Chan, D. et al.** Efficacy and safety of retreatment PRRT – A multi-centre Australian study

D06 **Chen, L. et al.** Preoperative CT radiomics decodes molecular characteristics and predicts high-risk molecular subgroup of pancreatic neuroendocrine tumors

D07 **Chen, J. et al.** Quantification of volumetric phenotypes in dual PET for survival analysis of NENs

D08 **Chupetlovska, K. et al.** AI-assisted quantitative imaging of liver tumor burden predicts survival and liver dysfunction in gastroenteropancreatic neuroendocrine tumor patients

D09 **Cristea, B. et al.** Evolution of patients with neuroendocrine tumors treated with peptide receptor radionuclide therapy: A retrospective analysis

D10 **Ćwikła, J. et al.** Convenient and effective way of dosimetry calculation in combined therapy using [177Lu]Lu-DOTATOC and CAPTEM in advanced progressive GEP-NET

D11 **Ćwikła, J. et al.** Evaluation of long-term PFS and OS in patients with advanced, non-resectable, progressive GEP-NET treated using combine [^{177}Lu]Lu DOTATOC and CAPTEM – Prospective single institution trail

D12 **d'Afflitto, M. et al.** Trial of Lu-177 DOTATATE (Lutathera®) in unlicensed indications: An interim analysis of the repeat peptide receptor radionuclide therapy (PRRT) cohort

D13 **Di Pangrazio, R. et al.** Ability of contrast-enhanced endoscopic ultrasound, strain ratio elastography and detective flow imaging to differentiate neuroendocrine and non-neuroendocrine pancreatic neoplasms

D14 **Dunin-Borkowska, A. et al.** Efficacy of local ablative techniques in GEP-NET liver metastases: Recurrence and survival outcomes from a UK Centre

D15 **Dureja, S. et al.** Impact of a nonprofit-led navigation program on PRRT readiness,

timeliness, and patient experience: Prospective pilot data from a low-volume Indian theragnostics centre

D16 **El Sabbagh, H. et al.** Identification of predictive factors of prolonged response to PRRT in patients with GEP-NETs

D17 **Engel, J. et al.** AI for lesion monitoring of neuroendocrine tumors under active surveillance

D18 **Eschrich, J. et al.** Multimodal deep learning for prediction of progression-free survival in patients with neuroendocrine tumors undergoing 177Lu-based peptide receptor radionuclide therapy

D19 **Fernando, H. et al.** Impact of PRRT on quality of life in functional NET

D20 **Ferreira, C. et al.** AI to flag SSTR imaging patterns predictive of poor PRRT outcomes

D21 **Ferreira, C. et al.** AI-guided stratification of PRRT candidates: Insights from current evidence and future directions

D22 **Ferreira, C. et al.** Alpha-emitter PRRT in neuroendocrine tumours: Current evidence, challenges, and future perspectives

D23 **Ferreira, C. et al.** Beyond SUV: Dynamic and kinetic PET modelling in somatostatin receptor imaging – A systematic review

D24 **Ferreira, C. et al.** Radiogenomic correlated of PRRT efficacy in neuroendocrine tumours: A systematic review of current evidence

D25 **Ferreira, C. et al.** Tumour microenvironment drivers of PRRT resistance: A systematic review of preclinical and clinical evidence

D26 **Fricke, J. et al.** Interim results of the BETA Plus Phase 0b Study: Targeted beta-plus conversion- and auger electron therapy with terbium-161 labeled somatostatin receptor antagonist DOTA-LM3

D27 **Gao, J. et al.** Tumor response and prognostic parameters derived from 68Ga-DOTANOC PET/CT in patients with neuroendocrine liver metastases treated with transarterial radioembolization

D28 **Gomez Sanchez, D. et al.** Role of routine CT scan in the diagnosis of carcinoid heart disease in metastatic neuroendocrine tumors: A retrospective multi-center Spanish study

D29 **Gonçalo, V. et al.** Portuguese experience with ^177Lu-DOTATATE in advanced digestive neuroendocrine tumors: A single-center retrospective analysis

D30 **Grana, C. et al.** Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumours: First clinical results of the NeoNet trial

D31 **Guan, K. et al.** The prognostic impact of tumour volume changes on [68Ga]DOTATATE PET/CT in NEN patients undergoing PRRT

D32 **Halfdanarson, T. et al.** Lutetium-177 DOTATATE PRRT in GEP-NETs: Hematologic toxicity trends, recovery profiles, and discontinuation rates

D33 **Halfdanarson, T. et al.** Real-world patterns of renal toxicity during peptide receptor radionuclide therapy for neuroendocrine tumors

D34 **Heinrich, M. et al.** Rechallenge PRRT: Maintaining safety and therapeutic potential

D35 **Jedamzik, T. et al.** Influence of harmonization-related resolution differences on [18F]FDG PET-based metabolic volumetry in patients with neuroendocrine neoplasms

D36 **Kolodziej, M. et al.** Dosimetry-guided radioligand therapy in neuroendocrine tumors: Interim safety analysis of the DUONEN trial

D37 **Kong, G. et al.** [18F]FDG (FDG) PET/CT biomarkers pre and post peptide receptor radionuclide therapy (PRRT) are prognostic in gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN)

D38 **Lafortune, R. et al.** The impact of preoperative 68Ga-DOTATATE positron emission tomography on the surgical management of small bowel neuroendocrine tumors

D39 **Li, Y. et al.** Risk assessment of type I gastric neuroendocrine tumors based on endoscopic and clinical features of autoimmune gastritis

D40 **Maciejewski, A. et al.** Evaluation of selected short-term endocrine effects in patients with neuroendocrine tumors treated with ^{177}Lu-DOTA-TATE

D41 **Mok, C. et al.** Efficacy of peptide receptor radionuclide therapy (PRRT) in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours (NETs)

D42 **Nicolas, G. et al.** [^{61}Cu]Cu-NODAGA-LM3 versus [^{68}Ga]Ga-DOTATOC in the same patients with neuroendocrine tumours: Preliminary results of the phase I/II COPPER-PET-in-NET trial

D43 **Otmane, R. et al.** Clinical impact of 99mTc-HYNIC-tektrotyd scintigraphy in the management of neuroendocrine tumors of unknown primary

D44 **Perrone, E. et al.** Can post-therapy SPET/CT predict clinical outcome in neuroendocrine neoplasms (NEN) patients treated with 177Lu-DOTATATE PRRT? A retrospective analysis

D45 **Perrone, E. et al.** Rescuing refractory G3 neuroendocrine neoplasms (NEN): Real-world clinical outcomes of alpha-PRRT using the SSTR antagonist DOTA-LM3

D46 **Polici, M. et al.** A machine learning model to predict response to Lutetium-177Lu-oxodotreotide therapy in patients with advanced gastroenteropancreatic neuroendocrine neoplasia: A retrospective single-centre study

D47 **Salcedo Cortes, S. et al.** Is there a correlation between metabolic tumor volume and progression-free survival in neuroendocrine tumors treated with lu-177-oxodotreotide?

D48 **Salcedo Cortes, S. et al.** Twice treated, still controlled: Long-term benefit of 177Lu-DOTATATE in NETs

D49 **Sasikumar, R. et al.** Persistent haematological toxicity after PRRT in neuroendocrine tumours: A 10-year regional UK experience

D50 **Schmidt, F. et al.** Safety and efficacy of radiolabeled somatostatin receptor antagonist [177Lu]Lu-DOTA-JR 11 for peptide receptor radionuclide therapy in patients with somatostatin receptor positive tumors – Interims analysis of a retrospective study

D51 **Schmidt, M. et al.** Use of somatostatin receptor (SSTR)-targeted radioligand therapy (RLT) in patients with pancreatic neuroendocrine tumors (panNET) in Germany

D52 **Tang, L. et al.** A preoperative CT-based radiomics model for predicting recurrence risk in pancreatic neuroendocrine tumors

D53 **Tang, W. et al.** Multi-task deep learning model to predict grade and lymph node metastasis in non-functional pancreatic neuroendocrine tumors (NF-PanNETs)

D54 **Walter, T. et al.** 177Lu-edotreotide for the treatment of pancreatic neuroendocrine tumours: A subgroup analysis from the COMPETE study

D55 **Xu, J. et al.** Predicting response to somatostatin analog therapy in GEP-NET liver metastases: A machine learning approach with ^{68}Ga-DOTATATE and ^{18}F-FDG PET/CT

D56 **Xu, J. et al.** The value of 18F-FDG and 68Ga-DOTANOC PETCT for GEP-NET with low Ki-67 index

D57 **Yuan, J. et al.** Role of tomoelastography in differentiating between non-functional pancreatic neuroendocrine neoplasms and solid pseudopapillary neoplasms

D58 **Zhengkun, D. et al.** Automated hybrid dosimetry and vertebral dose-toxicity correlation in [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy

E | Clinical Science – Medical Treatment

E01 **Aicha, B. et al.** Bone metastases in digestive NETs: Incidence, predictors, and survival outcomes – NETWORK WEST

E02 **Beck da Silva Etges, A. et al.** Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors (NET)

E03 **Becx, M. et al.** Applying ^{177}Lu-DOTATATE for hereditary neuroendocrine tumours: The role in MEN1

E04 **Cao, D. et al.** Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomized, controlled trial

E05 **Capdevila, J. et al.** DAREON®-7: Phase I open-label dose-escalation/expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

E06 **Cerantola, R. et al.** Oxaliplatin- and temozolomide-based therapy in metastatic GEP-NETs: A monocentric comparison

E07 **Chauhan, A. et al.** A phase I trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms

E08 **Chauhan, A. et al.** Phase I trial of M3814 (peposertib) in combination with Lutetium 177 DOTATATE for metastatic well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

E09 **Chi, Y. et al.** Survival benefits of adjuvant somatostatin analogues therapy in patients with gastroenteropancreatic neuroendocrine tumors: A Chinese multi-institutional propensity score matched and weighted analysis (CASANET-gep)

E10 **Cives, M. et al.** A phase II study of cabozantinib and temozolomide in advanced neuroendocrine tumors

E11 **Coletta, M. et al.** Vitamin D status in G1 gastric neuroendocrine tumors: Any difference with other primary sites?

E12 **Di Iasi, G. et al.** Ectopic hormone syndrome in neuroendocrine tumors: A 20-year retrospective series from a monocentric ENETS Center of Excellence

E13 **Dugmore, S. et al.** Chemotherapy use and its effect on overall survival in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN): A population-based study of 63,911 patients

E14 **Fan, Y. et al.** Liposomal Irinotecan plus platinum chemotherapy in neuroendocrine neoplasms: A real-world study

E15 **Folkestad, O. et al.** The relationship between dose, concentration and toxicity of everolimus in the treatment of neuroendocrine tumors: A prospective observational study

E16 **Frydman, A. et al.** Special considerations in patients with neuroendocrine tumours referred for PRRT

E17 **Garcia Alvarez, A. et al.** First-line streptozotocin vs temozolomide-based chemotherapy in advanced neuroendocrine tumors: Real-world comparison from the Spanish GETNE registry

E18 **Guérin, A. et al.** Treatment patterns and outcomes among unresectable/metastatic GEP-NETs patients previously treated with SSA

E19 **Hajac, L. et al.** Investigator-assessed disease progression in a phase II study of paltusotine in patients with neuroendocrine tumors and carcinoid syndrome

E20 **Hayes, A. et al.** FOLFIRI after failure of platinum-based chemotherapy in poor prognostic neuroendocrine neoplasms of gastroenteropancreatic origin – A real-world evidence study

E21 **Hu, H. et al.** Clinical features and management options for duodenal neuroendocrine tumors: A retrospective, single-center study

E22 **Iizuka, T. et al.** Clinical outcomes and safety of peptide receptor radionuclide therapy in Japanese patients with metastatic rectal neuroendocrine neoplasms

E23 **Ikeda, M. et al.** Integration of the revised treatment selection MAP and NEN policy recommendation for gastroenteropancreatic neuroendocrine tumors in Japan

E24 **Inoue, K. et al.** A multi-center retrospective study of temozolomide plus capecitabine in patients with pancreatic neuroendocrine tumors in Japan

E25 **Jia, X. et al.** Efficacy, safety, and prognostic factors of capecitabine plus temozolomide regimen in patients with thymic neuroendocrine tumors: A 178-case multi-center retrospective study

E26 **Jian, W. et al.** Is a dedicated MGMT-NET trial warranted in grade 3 NETs? An inverse probability of treatment weighting comparison of first-line oxaliplatin and temozolomide-based chemotherapy in G3 NETs and the impact of MGMT expression

E27 **Jóźwik-Plebanek, K. et al.** Radioligand therapy in lung neuroendocrine tumors: Prognostic

factors and long-term outcomes

E28 **Ke, Y. et al.** Efficacy and safety of MHB088C in patients with advanced extrapulmonary neuroendocrine carcinoma after platinum-based therapy failure: An open-label, single-arm, single-center phase II study

E29 **Kolodziej, M. et al.** Tandem [^{90}Y]Y/[^{177}Lu]Lu-DOTATATE therapy in neuroendocrine tumors: The largest long-term real-world experience from Poland

E30 **Koumarianou, A. et al.** Somatostatin analogs in advanced typical and atypical pulmonary carcinoids: A multi-center retrospective analysis from Lung NET database

E31 **Leone, V. et al.** Radioligand therapy in well-differentiated neuroendocrine tumors: Insights into bone metastasis response and progression patterns from a single-center retrospective study

E32 **Li, X. et al.** Personalizing postoperative surveillance: A risk-stratified predictive model based on Lasso-Cox regression and random survival forest for postoperative progression of gastrointestinal neuroendocrine neoplasms

E33 **Liang, Y. et al.** Clinicopathological features and treatment outcomes of well-differentiated primary renal neuroendocrine tumors: A two-center retrospective study

E34 **Liang, Y. et al.** Systemic therapy for advanced pheochromocytoma and paraganglioma: Real-world evidence from a single-center cohort

E35 **Lin, Z. et al.** Updated efficacy and safety of surufatinib combined with EP regimen and serplulimab as first-line therapy for neuroendocrine carcinoma

E36 **Markovich, A. et al.** Type 1 gastric NETs: Adjuvant therapy with somatostatin analogues

E37 **Melhorn, P. et al.** Descriptive and prognostic analysis of the oligometastatic disease state in enteropancreatic neuroendocrine tumors

E38 **Melo, S. et al.** Descriptive analysis of metastatic lung carcinoid tumors: A decade of single-center experience

E39 **Merola, E. et al.** High-grade gastroenteropancreatic neuroendocrine neoplasms: An overlooked population in interventional clinical trials – A systematic review

E40 **Montiel, E. et al.** Efficacy and safety of modified FOLFIRINOX compared to platinum-etoposide/irinotecan in metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC): A multi-center retrospective study

E41 **Murphy, G. et al.** Diagnosis, treatments and prognostic factors in the management of gastrinomas

E42 **Pusceddu, S. et al.** LOLA trial: Phase II trial with combination of cabozantinib plus lanreotide – Final results of extrapancreatic neuroendocrine tumor (EP-NET) cohort

E43 **Putraveephong, S. et al.** Outcomes and prognostic factors in advanced gastroenteropancreatic neuroendocrine carcinoma treated with first-line chemotherapy

E44 **Ramos Olivares, J. et al.** Capecitabine/temozolomide or single agent temozolomide in typical and atypical lung neuroendocrine tumours

E45 **Reinecke, J. et al.** First analysis of CABONEN – A multi-center phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3

E46 **Shekhda, K. et al.** PTHrP-secreting pancreatic neuroendocrine tumours: Clinical characteristics, management, and outcomes of humoral hypercalcaemia of malignancy

E47 **Sun, X. et al.** Surufatinib plus octreotide LAR in patients with grade 1/2 GEP-NETs: A single-arm, prospective, open-label phase II study

E48 **Sun, Z. et al.** The mutational and immunotherapeutic landscape of high-grade neuroendocrine neoplasms

E49 **Tuerff, D. et al.** Real-world safety and dose adjustments of cabozantinib in neuroendocrine tumors

E50 **Vandamme, T. et al.** Real-world effectiveness of lanreotide autogel (LAN) in advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs), stratified by Ki-67 proliferation index (Ki-67) and primary tumour location: Post-hoc analyses from KINETICS

E51 **Vijayvergia, N. et al.** Real-world patient characteristics, treatment patterns and clinical outcomes in patients diagnosed with extrapulmonary neuroendocrine carcinoma (epNEC): A non-interventional multimodal database analysis in the US

E52 **Wang, J. et al.** 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumors: A systematic review and meta-analysis

E53 **Wang, H. et al.** S-1/temozolomide for the treatment of locally advanced or metastatic paraganglioma: A real-world analysis of efficacy and safety

E54 **Wang, J. et al.** Surufatinib plus hepatic artery infusion chemotherapy (HAIC) as second-line and maintenance therapy for neuroendocrine carcinoma with liver metastases: Updated results from a single-arm, open-label, phase II study

E55 **Yin, X. et al.** Treatment strategies for small cell carcinoma of the esophagus: A real-world comparative analysis of multimodal regimens across two independent cohorts

E56 **Yu, F. et al.** Real-world evidence for Qizhen Yiliu formula in non-functional pancreatic neuroendocrine tumors after radical resection: A multi-center, retrospective study with propensity score matching

E57 **Zhao, X. et al.** A real-world study of surufatinib combined with octreotide LAR in the treatment of advanced neuroendocrine tumors

F | Basic Science

F01 **Almeamar, H. et al.** Expression of somatostatin receptors in circulating extracellular vesicles and association with response to somatostatin receptor-based therapies in well-differentiated neuroendocrine tumours

F02 **Battistella, A. et al.** Complementary roles of patient-derived tumoroids and precision-cut tumor slices in evaluating targeted therapy response in non-functioning pancreatic neuroendocrine tumors

F03 **Boehm, E. et al.** Comparison of circulating tumour DNA (ctDNA) across NEN subtypes and investigation of ctDNA clinical utility in the care of patients with neuroendocrine neoplasms

F04 **Bolduan, F. et al.** Transcriptomic analysis of small intestinal neuroendocrine tumors reveals reduced REST expression and enteroendocrine cells as cell of origin

F05 **Castanho Martins, M. et al.** Understanding liver metastasis predisposition in SI-NETs – Investigating the impact of PNPLA3 rs738409 single nucleotide polymorphism on establishing a hepatic pre-metastatic niche

F06 **Castanho Martins, M. et al.** Unravelling the molecular mechanisms behind mesenteric fibrosis: Analysing epigenetic and transcriptomic profiles for target gene identification

F07 **d'Afflitto, M. et al.** Imaging and molecular annotation of the small intestinal neuroendocrine tumour microenvironment

F08 **Dai, S. et al.** Dynamic transcriptomic evolution of non-functional pancreatic neuroendocrine tumors and validation of prognosis-related core stratification biomarkers

F09 **Däubler, C. et al.** Impact of neuroendocrine neoplasm-specific systemic treatments on CXCR4 expression and function in neuroendocrine tumor cells

F10 **Däubler, C. et al.** Impact of neuroendocrine neoplasm-specific systemic treatments on SSTR expression and function in neuroendocrine tumor cells

F11 **Dellavalle, S. et al.** Molecular and metabolic landscapes of pancreatic and ileal neuroendocrine tumors: Insights from multi-omics integration

F12 **Elias, E. et al.** Early initiation of small intestine neuroendocrine tumors

F13 **Fabretti, F. et al.** Study of the sonic hedgehog signaling pathway in gastric neuroendocrine neoplasms

F14 **Filice, A. et al.** Interplay between body composition and immunophenotype in patients with gastroenteropancreatic neuroendocrine tumors: Results of a cross-sectional study

F15 **González-Pérez, C. et al.** High-throughput sequencing reveals recurrent mutations in snRNA genes in pancreatic neoplasms

F16 **Gutiérrez-Camacho, L. et al.** Alternative splicing of CD44 reveals isoform-specific dysregulation associated with tumor grade in lung neuroendocrine tumors (lungNETs)

F17 **Han, X. et al.** The METTL1-tRNA m7G-SMOC1 axis promotes pancreatic neuroendocrine neoplasms proliferation by driving cell cycle progression

F18 **Hernandez Llorens, M. et al.** PTPRN as a key regulator of neuroendocrine tumours (NETs)

F19 **Hodgetts, H. et al.** Transcriptomic and proteomic characterisation of mesenteric fibrosis in small intestinal neuroendocrine tumours

F20 **Hunaut, T. et al.** Transcriptomic abnormalities of familial small intestine neuroendocrine tumors: A study from the French GTE-RENATEN network

F21 **Islam, O. et al.** Pathway-targeted combination screening in 3D-spheroids reveals synergistic interactions with everolimus in pancreatic neuroendocrine tumors

F22 **Jiang, Y. et al.** Plasma lipid metabolite-based early diagnostic model reveals enhanced omega-oxidation as a metabolic hallmark of pancreatic neuroendocrine tumors

F23 **Jumai, N. et al.** Deciphering the mechanisms of IGF2-mediated liver metastases in pancreatic neuroendocrine tumor through single-cell RNA sequencing

F24 **Jungen, H. et al.** Tracing tumor evolution in pulmonary neuroendocrine cancer using patient-derived tumor organoids

F25 **Kalendauskas, A. et al.** Metabolomic Profiles and Sex-Specific Metabolic and Survival Phenotypes in Neuroendocrine Neoplasms: Findings from the UK Biobank

F26 **Kirchner, P. et al.** DNA methylation-based classifier identifies prognostically distinct subtypes of pancreatic neuroendocrine tumors

F27 **Klaas, L. et al.** Establishing and characterizing patient-derived organoids from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) as a model to study efficacy and mechanisms of radioligands in vitro

F28 **Kumar, S. et al.** Integrating patient-derived organoids to uncover synergistic efficacy of romidepsin and everolimus in pancreatic neuroendocrine tumors

F29 **Li, X. et al.** The role and mechanism of FDFT1 in regulating macrophage activation in pancreatic neuroendocrine tumors

F30 **Lu, H. et al.** PRKDC inhibition as a novel radiosensitization strategy in advanced prostate cancer through NHEJ-targeted synthetic lethality

F31 **Mayere, E. et al.** Patient derived tumoroids culture predicts pancreatic neuroendocrine tumor patients response to temozolomide

F32 **Morken, S. et al.** Evolution of neuroendocrine and adenocarcinoma components in colorectal mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN)

F33 **Mraihi, N. et al.** FAK inhibition restores therapeutic sensitivity in gastrointestinal neuroendocrine tumors

F34 **Nabariya, D. et al.** Understanding the role of extracellular vesicles in small intestinal neuroendocrine tumors

F35 **Nowicka, G. et al.** The assessment of efficacy of combine therapy using [177Lu]Lu DOTA-TOC and CAPTEM in advanced, non-resectable, progressive GEP-NET based on blood transcript profiling

F36 **Pawlak, G. et al.** Integrative gene regulatory network analysis reveals mutation-specific transcriptional programs in pancreatic neuroendocrine tumors

F37 **Pecora, G. et al.** Synergistic antitumor effects of statins and somatostatin analogues in lung neuroendocrine tumors: An in vitro investigation

F38 **Pedraza-Arévalo, S. et al.** How an old dog learns new tricks: GNAS splicing as a potential contributing driver to dedifferentiation in lung neuroendocrine tumors (LungNETs)

F39 **Peng, J. et al.** AGR2-high cells drive a FOXM1-mediated pro-malignancy program in Non-functional pancreatic neuroendocrine tumors (NF- PanNETs) and informatively predict

patient outcomes

F40 **Ruiz-Palacios, D. et al.** Dissecting the interplay between RNA splicing and m6A methylation in neuroendocrine neoplasms biology

F41 **Sabella, G. et al.** Unrevealing spatial differences in a cohort of highly proliferative lung carcinoids with the GeoMx® Digital Spatial Profiler

F42 **Schiller, A. et al.** Multiomics characterization of multifocal small intestine neuroendocrine tumors

F43 **Sexton-Oates, A. et al.** A clinically relevant morpho-molecular classification of lung neuroendocrine tumours

F44 **Tihy, M. et al.** Histological classification of high-grade digestive neuroendocrine neoplasms using an advanced deep learning model

F45 **Tornesello, M. et al.** Anticancer activity of cabozantinib and temozolomide in typical bronchial carcinoid and in pancreatic neuroendocrine tumor cell lines

F46 **Ullmann, C. et al.** Drug-tolerant pannen cells as precursors of acquired resistance: Opportunities for early intervention against relapse

F47 **Viol, F. et al.** FGF/FGFR signalling contributes to tumor growth in gastroenteropancreatic neuroendocrine tumors: First results of an in vitro study

F48 **Wang, Y. et al.** Disrupted pseudocapsule promotes ANXA1^{+} myCAF-mediated IGFBP2 secretion and reduces PD-L1–dependent immunotherapy sensitivity in PanNETs

F49 **Wang, W. et al.** Profiling the genetic landscape of gastric neuroendocrine carcinomas via whole-exome sequencing and identification of actionable drug targets

F50 **Wang, K. et al.** Standardised platform for drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms

F51 **Wolfshöfer, S. et al.** mTORC1 and mTORC2 dual blockade suppresses growth of everolimus-resistant pancreatic neuroendocrine tumor cell lines

F52 **Ye, M. et al.** Crosstalk between pancreatic neuroendocrine tumor cells and pancreatic stellate cells promotes tumor progression through immunosuppression

F53 **Ye, M. et al.** Exosomes derived from tumor cells promote liver metastasis of pancreatic neuroendocrine tumors by activating hepatic stellate cells

G | Clinical Science – Surgical Topics

G01 **Albanesi, F. et al.** A promising role of PRRT prior to liver transplantation: Expanding possibilities for metastatic GEP-NETs

G02 **Ammann, M. et al.** Cytoreductive hepatectomy remains effective in carcinoid heart disease

G03 **Ammann, M. et al.** Prognostic significance of carcinoid syndrome beyond tumor burden in small bowel NET liver metastases undergoing cytoreductive hepatectomy

G04 **Bertolaccini, L. et al.** An artificial intelligence–assisted, interpretable prognostic tool for

mortality risk in lung neuroendocrine tumors

G05 **Bertolaccini, L. et al.** External validation of the Rachel score in lung neuroendocrine tumors: Prognostic accuracy and clinical utility

G06 **Dai, S. et al.** Long-term outcomes of surgery versus observation for small non-functional pancreatic neuroendocrine tumors ≤ 3cm: A cohort analysis of 1973-2021 SEER data

G07 **Danieli, M. et al.** Role of primary tumor resection on outcomes of metastatic small intestine neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy

G08 **Iliakopoulos, K. et al.** Second neoplasms in patients with sporadic neuroendocrine neoplasms (NENs)

G09 **Konyakhina, A. et al.** Treatment outcomes for localized pulmonary carcinoids: A single-center experience

G10 **Lafortune, R. et al.** Prevalence of occult microscopic ovarian metastases in the context of small bowel neuroendocrine tumours: A multi-centric study

G11 **Milanetto, A. et al.** Pancreatic neoplastic involvement in small intestinal neuroendocrine neoplasms

G12 **Milanetto, A. et al.** Sporadic pancreatic neuroendocrine neoplasms in patients with age ≥ 75 years – Surgery or surveillance?

G13 **Mortagy, M. et al.** Does surgical resection improve survival of pancreatic neuroendocrine tumours (PanNET) less than 2 cm? A population-based study of 4,114 patients comparing England and the USA

G14 **Parati, C. et al.** Impact of cytoreductive surgery before PRRT on oncologic outcomes in metastatic NENs: A systematic review

G15 **Podrascanin, V. et al.** Cause of death after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: A single-center retrospective analysis

G16 **Podrascanin, V. et al.** The overarching prognostic role of tumor progression prior to cytoreductive hepatectomy in NETLM

G17 **Podrascanin, V. et al.** The paradox of grade 2 pancreatic neuroendocrine tumors: G2a/G2b subdivision in patients with and without liver metastases – A retrospective single-center analysis

G18 **Podrascanin, V. et al.** The role of primary tumor resection in surgical management of asymptomatic metastatic PNETs – A retrospective single-center study

G19 **Ritter, A. et al.** Preoperative malnutrition is a frequent risk factor in patients with pancreatic neuroendocrine tumours

G20 **Sarzo, C. et al.** Post-operative patient-reported symptom burden in entero-pancreatic neuroendocrine tumors – A population-level analysis

G21 **Simou, C. et al.** Surgical management and survival outcomes of pancreatic neuroendocrine neoplasms: Insights from a single-centre experience

G22 **Sorbye, H. et al.** Treatment, recurrence and survival in 277 patients with stage I-III digestive

neuroendocrine carcinoma – Preliminary results from an ENETS initiated retrospective cohort study

G23 **Tan, K. et al.** Is resection of small bowel primary NET justified in stage IV disease? Evidence from 2,400 patients in two national population-based registries

G24 **Tasouli, E. et al.** Liver resection for neuroendocrine neoplasm metastases: Patient characteristics and survival outcomes

G25 **Tasouli, E. et al.** Surgical outcomes in small bowel neuroendocrine tumours: A contemporary single-centre experience

G26 **Thiis-Evensen, E. et al.** Liver transplantation in patients with neuroendocrine tumors – The Oslo experience

G27 **von Kroge, P. et al.** Hepatically metastasized neuroendocrine tumours of the gastroenteropancreatic system are safely approachable with simultaneous resection

G28 **Wei, K. et al.** New sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: A systematic review and meta-analysis

G29 **Xingwu, Z. et al.** Intraoperative blood glucose monitoring using continuous glucose monitoring (CGM) in patients with insulinoma: A descriptive study

G30 **Zahoor, D. et al.** Current approaches to surgical and non-surgical management of neuroendocrine tumor liver metastases: Revisiting debulking thresholds and emerging therapies

G31 **Zhang, L. et al.** The prognostic value of metabolic syndrome and lipid accumulation product index in patients with resectable non-functional pancreatic neuroendocrine tumors

H | Clinical Science – Other

H01 **Abdalrazag, O. et al.** Continuous glucose monitoring (CGM) prior to 72 hours fast: Real-world data from a Center of Excellence on diagnostic efficacy and cost effectiveness

H02 **Aktypis, C. et al.** Vascular remodelling in treated patients with gastroenteropancreatic neuroendocrine tumours

H03 **Bartsch, D. et al.** Characteristics and outcome of VIPoma – A retrospective analysis of the ENETS Database

H04 **Grewal, U. et al.** Online patient and caregiver conversations focused on neuroendocrine neoplasms: A global thematic analysis

H05 **La Salvia, A. et al.** Evaluating quality of life endpoints in phase III randomized trials for neuroendocrine tumors: A 15-year overview

H06 **Le Berre, M. et al.** Impact of an online educational activity on clinicians' knowledge and confidence regarding the management of lung neuroendocrine tumours

H07 **Liu, Z. et al.** Clinicopathological features and prognostic analysis of thymic neuroendocrine tumors with bone metastasis

H08 **Liu, H. et al.** Immune microenvironmental evolution and tertiary lymphoid structure in progressive neuroendocrine tumors after multimodal therapy

H09 **Mariën*, L. et al.** Germline MEN1 testing patterns in young patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, ENETS Center of Excellence

H10 **Mortagy, M. et al.** Is it time to screen for second primary malignancies in gastroenteropancreatic neuroendocrine tumour? A population-based analysis of 85,614 patients

H11 **Nageshwaran, S. et al.** Extrachromosomal DNA detection in neuroendocrine carcinomas: A pilot whole-genome sequencing study

H12 **Osaki, L. et al.** The functional edge: Opportunities and obstacles in precision oncology for neuroendocrine tumors

H13 **Perelmuter, M. et al.** Body composition phenotypes in patients with neuroendocrine tumors at diagnosis

H14 **Perrier, M. et al.** Palliative care referral and impact on survival after discontinuation of anticancer treatments in patients with metastatic high-grade G3 neuroendocrine neoplasms

H15 **Raia, S. et al.** Association between BMI at diagnosis and development of bone metastases in non-functioning pancreatic neuroendocrine tumors: A monocentric retrospective study

H16 **Ritter, A. et al.** Helicobacter pylori is a risk factor in small intestinal neuroendocrine tumour growth

H17 **Rueda, M. et al.** Clinical and surgical characterization of patients with non-functional pituitary tumors who developed postoperative diabetes insipidus at the Hospital San José de Bogotá, in Bogotá, Colombia

H18 **Spada, F. et al.** Efficacy, effectiveness, safety, health-related quality of life and patient reported outcomes of lanreotide beyond first-line monotherapy in neuroendocrine tumours: A systematic literature review

H19 **Wang, J. et al.** Systematic review and meta-analysis of peptide receptor radionuclide therapy in the retreatment of neuroendocrine tumors

H20 **Wotherspoon, I. et al.** An exploration of pancreatic NET referred to the Beatson West of Scotland Cancer Centre 2015-2020

H21 **Wotherspoon, I. et al.** Management and outcomes of patients with small pNET

H22 **Zhao, Q. et al.** Transarterial embolization plus octreotide LAR in treating rectal neuroendocrine tumor liver metastases ： A single-institutional experience

H23 **Zhou, C. et al.** A bibliometric analysis of the scientific trajectory of rectal neuroendocrine neoplasms

H24 **Zhou, C. et al.** Evaluating the quality and reliability of neuroendocrine neoplasms related videos on YouTube, Bilibili, and Tiktok: A cross-sectional analysis

H25 **Zhou, Y. et al.** Exploring symptoms, impacts, and bothersomeness in patients with

extrapulmonary neuroendocrine carcinoma (epNEC)

I | Case Reports

I01 **Abdul Onny, M. et al.** Navigating clinical complexities: Early Malaysian experience with MIBG therapy for adult inoperable malignant paraganglioma

I02 **Al-Saffar, A. et al.** Adrenaline secreting retrocaval paraganglioma

I03 **Al-Saffar, A. et al.** Double trouble: A rare case of vasoactive intestinal peptide and calcitonin co-secreting pancreatic neuroendocrine tumor presenting with refractory diarrhea

I04 **Al-Saffar, A. et al.** Double trouble: Synchronous adrenal pheochromocytoma and pancreatic insulinoma – Diagnostic and therapeutic challenges

I05 **Barkmanova, J. et al.** Three cases of unusual metastatic sites in well-differentiated NETs and their management

I06 **Battistella, A. et al.** Mesenteric paraganglioma: The unusual suspect

I07 **Behourah, Z. et al.** Pancreatic neuroendocrine tumor as the initial manifestation of MEN1 syndrome: A case report

I08 **Boudersa, A. et al.** Rare association of a monodermal teratoma and metastatic neuroendocrine tumor of the ovary in a young woman

I09 **Cai, W. et al.** A successful clinical case from "NALIRIFOX as second-line chemotherapy in extrapulmonary high-grade neuroendocrine neoplasms: A prospective, single-center, single-arm trial (NCT07077551)"

I10 **Carroll, H. et al.** Primary renal neuroendocrine tumour masquerading as renal cell carcinoma: A case report

I11 **Chen, X. et al.** A somatostatin receptor negative rectal neuroendocrine tumor with extensive metastases: A case report

I12 **Cillero, I. et al.** Long-term disease control with 177Lu-DOTATATE in a metastatic pancreatic neuroendocrine tumour with concomitant multiple myeloma: A case report

I13 **Cillero Etxebeste, I. et al.** Complete resolution of severe refractory hypoglycaemia following Lutetium-177 DOTATATE peptide receptor radionuclide therapy in a metastatic dual insulinoma-gastrinoma pancreatic neuroendocrine tumour: A case report

I14 **Ciobanu, O. et al.** Somatostatinoma syndrome: Diagnostic challenges in a rare neuroendocrine tumor

I15 **Corrêa Figueira, C. et al.** Phenotypic plasticity in pancreatic neuroendocrine tumors – A case of acquired insulinoma

I16 **Duan, J. et al.** Dynamic changes in parathyroid hormone following treatment of PTHrP-mediated hypercalcemia in pancreatic neuroendocrine tumors

I17 **Dunões, I. et al.** BRAF-mutated ileal neuroendocrine carcinoma responding to targeted

therapy: A case report

I18 **Galbraith, E. et al.** Case report: CDKN1B mutation variant in paraganglioma-multiple pulmonary neuroendocrine tumour phenotype – The value of the NET MDT

I19 **González Devia, D. et al.** Diagnostic and therapeutic challenges in Dercum's disease associated with neuroendocrine neoplasms: Report of three clinical cases

I20 **Hernando Cubero, J. et al.** First experience with ^{177}Lu-DOTATATE in an acinar cell carcinoma of the pancreas with neuroendocrine differentiation: A case report

I21 **Huang, X. et al.** A case of rapid recurrence and liver metastasis following radical resection for neuroendocrine carcinoma of the gastroesophageal junction

I22 **Inchaustegui Tinajero, J. et al.** Multifocal small bowel neuroendocrine tumor presenting in association with intramueral lipomas, unusual presentation with successful surgery: A case report

I23 **Kerolles, M. et al.** Multifocal, metastatic secondary gastric NET due to germline proton pump mutations (ATP4A): A case report and targeted NGS analysis

I24 **Khalifa, S. et al.** Breast metastasis arising from ileal neuroendocrine tumor: An unusual presentation – Case report and literature review

I25 **Lefebvre, L. et al.** Transformation of a metastatic pancreatic non-functioning neuroendocrine tumor into an insulinoma 19 years after initial diagnosis

I26 **Li, X. et al.** Aggressive pancreatic mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with liver metastasis: A case report

I27 **Liang, T. et al.** Pancreatic neuroendocrine tumor with elevated AFP liver metastasis MDT case report

I28 **Martin, C. et al.** A rare association of synchronous tumors: Metastatic jejunal adenocarcinoma and strumal carcinoid in young age patient

I29 **Musiałkiewicz, J. et al.** Carcinoid syndrome as the initial presentation of large-cell neuroendocrine carcinoma of unknown origin – A rare case report

I30 **Nour, B. et al.** Gallbladder neuroendocrine tumor with hepatic metastasis: A case report and literature review

I31 **Otmane, R. et al.** Pulmonary DIPNECH and adrenal involvement in a patient with medullary thyroid carcinoma: The role of Tektrotyd® scintigraphy

I32 **Ponte, M. et al.** Solitary cardiac metastasis of an ileal neuroendocrine tumor: Two-year outcome after stereotactic radiotherapy

I33 **Rossi, M. et al.** High microsatellite instability (MSI-H) and tumor mutational burden (TMB-H) in a well-differentiated pancreatic neuroendocrine tumor (Pan-NET): Potential biomarkers for personalized therapy

I34 **Serban, A. et al.** A case of multifocal typical pulmonary carcinoid in the setting of DIPNECH with ectopic ACTH secretion

I35 **Silva, B. et al.** Peptide receptor radionuclide therapy in the management of aggressive

pituitary macroadenoma

I36 **Stefańska, A. et al.** Everolimus as a treatment option for advanced thymic neuroendocrine neoplasms

I37 **van 't Veld, B. et al.** Molecular evidence against a lynch-associated origin of pancreatic neuroendocrine tumors: A case report and comprehensive study of literature

I38 **Xu, J. et al.** GLP-1R PET/CT guiding the excision of gastrinoma

I39 **Zahoor, D. et al.** Intestinal-type gastric neuroendocrine tumor with synchronous pancreatic mass: A rare case

I40 **Zerrouk, D. et al.** Well-differentiated pancreatic neuroendocrine tumor with a minor ductal adenocarcinoma component in a young woman: A rare mixed neoplasm case

I41 **Zheng, C. et al.** Pancreatic neuroendocrine tumor presenting with diffuse enlargement of pancreas and duodenal papilla mass: A case report

J | Trials-in-Progress / Trial Concepts

J01 **Cai, W. et al.** NALIRIFOX as second-line chemotherapy in extrapulmonary high-grade neuroendocrine neoplasms: A prospective, single-center, single-arm trial

J02 **Chauhan, A. et al.** ETCTN 10558: A phase II randomized control trial of triapine plus Lutetium 177 DOTATATE versus Lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors

J03 **Chauhan, A. et al.** NET RETREAT: A CCTG-SWOG phase II study of 177Lutetium-DOTATATE retreatment vs. standard of care in metastatic GEP-NET patients

J04 **Filice, A. et al.** Italian multi-center experience on peptide receptor radionuclide therapy (PRRT) in pheochromocytomas and paragangliomas: A retrospective analysis on behalf of the ITANET centers network

J05 **Garcia-Carbonero, R. et al.** CAREFNDR: Phase III, randomized, placebo-controlled study of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors

J06 **Janssens*, K. et al.** The 1000-NEN-Genome project: An European-Australian whole genome sequencing initiative to uncover germline predisposition for neuroendocrine tumors

J07 **Lamarca, A. et al.** First-in-human study of a novel nonpeptide drug conjugate (CRN09682) in patients with somatostatin receptor 2-expressing tumors

J08 **Mulargiu, C. et al.** Development and validation of an epigenomics-based liquid biopsy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN): A translational and prospective study

J09 **Salimgereeva, D. et al.** Tactics optimization in localized pancreatic neuroendocrine tumours

J10 **Singh, S. et al.** Zanzalintinib versus everolimus in patients with previously treated advanced neuroendocrine tumors: A randomized Phase II/III clinical trial (STELLAR-311)

J11 **Weich, A. et al.** CABOLIFE: Design of a prospective non-interventional study evaluating cabozantinib in real-world treatment of neuroendocrine tumours

K | Nursing and Allied Health Topics

K01 **de Weerdt, C. et al.** Enhancing clinical trial access for NEN patients through a cross-site 'flying' study coordinator within NETwerk – ENETS Center of Excellence

K02 **Ferreira, C. et al.** Sustainable nuclear medicine: Environmental impact and future directions in PRRT and SSTR imaging

K03 **Grana, C. et al.** The importance of patients' associations in the access to therapies for neuroendocrine tumors

K04 **Ho, J. et al.** Implementation of the MASCC Oral Agent Teaching Tool (MOATT) in nurse consultations for patients with neuroendocrine and hepatobiliary-pancreatic cancers: Exploration of acceptability, feasibility and satisfaction

K05 **Manna, A. et al.** Exploring palliative care for neuroendocrine cancer patients in rural India

K06 **Vignon, S. et al.** Lived experiences and biopsychosocial challenges in the daily lives of patients affected by multiple endocrine neoplasia type 1